The physical health of people with severe mental illness has quite rightly been subjected to increased focus over recent years. Patients with a severe mental illness (SMI) have been shown to suffer increased morbidity and mortality from a variety of physical health conditions, including cardiovascular disease, cerebrovascular disease, obesity and type 2 diabetes, respiratory disease and some forms of cancer. (Brown et al., 2000; Dalton et al., 2005; Osborn et al., 2007) . Most of the recent focus has been on cardiovascular and metabolic disease as reflected by recent guidelines on this topic (Barnett et al., 2007) .
Hyperprolactinaemia in the SMI population has received less attention, and is less easily recognised than other drug side effects, such as extrapyramidal symptoms (EPS) or weight gain. The diagnosis of hyperprolactinaemia requires a blood test. The consequences themselves are often hidden or take many years to develop and the clinical significance of these consequences, the focus of this supplement (Hyperprolactinaemia in schizophrenia and bipolar disorder: Clinical Implications, 2008), are relatively unknown. There is little awareness of either the extent of the prevalence or the severity of hyperprolactinaemia, although hyperprolactinaemia is often the most common side effect reported in clinical trials (Bushe and Shaw, 2007) . Indeed the prescribing information for antipsychotics includes information about prolactin elevation and its possible consequences although currently it offers no guidance on diagnosis or monitoring.
Eighty years before the introduction of the first antipsychotics, amenorrhoea, a symptom that is now sometimes associated with hyperprolactinaemia and antipsychotic drugs, was already reported in patients with schizophrenia. Kohen and Wildgust take the reader through this early history. Although these symptoms were not necessarily related to prolactin, they were probably associated with stress on the hypogonadal system in very disturbed patients and schizophrenia itself may be an integral risk factor. Specific symptoms of hyperprolactinaemia such as galactorrhoea were not reported until after the introduction of antipsychotics.
The hormone prolactin was identified by Riddle et al. (1933) from the crop-glands of pigeons although before the 1970s scientists doubted that it actually existed in humans. The first reports of symptomatic hyperprolactinaemia, galactorrhoea, quickly followed the introduction of antipsychotics in the 50s, and Sulman and Winnik (1956) intuitively associated these side effects to prolactin as they stated that 'The prolonged increase of 'unbalanced tropins', especially of prolactin, results in production of colostrum or galactorrhoea'. The pivotal development of radio-immune-assays in the early 1970s allowed purification of prolactin as a separate hormone and accurate measurement of prolactin levels. This enabled new studies to bring a clearer understanding of its role and the concept of too much prolactin -hyperprolactinaemia. Many drugs elevate prolactin. Beumont et al. (1974) and Meltzer et al. (1974) were among the first to report antipsychotic drugs, however, for the next 30 years there were few clinical studies reporting prolactin data in any meaningful manner. In contrast to many other adverse events, the prevalence and severity of hyperprolactinaemia was rarely reported even for new antipsychotics (Kane et al., 2007; Bushe and Shaw, 2007) . Since there were no alternative treatments to early antipsychotics, hyperprolactinaemia was deemed almost inevitable, although the higher doses used contributed to this erroneous perception. The silent nature of some of the prolactin symptoms may have been further reasons for a paucity of research. During the first 40 years of treatment with typicals there was little discussion about the impact on sexual function or fertility, which are given more attention in a whole-person approach to medicine and psychiatry.
Fitzgerald and Dinan explore the connection between dopamine and prolactin and the latest theories behind antipsychoticinduced hyperprolactinaemia. Differential D2 receptor site occupancy and rates of dissociation from D2 receptor sites, together with differential blood-brain-barrier deposition have been postulated as mechanisms for the varying degrees of prolactin elevation among antipsychotics. Randomised controlled trials have shown a range of effects of antipsychotics on prolactin levels that broadly agree with their dopaminergic properties. Antipsychotics have thus been simply categorised into prolactin sparing and prolactin raising, which is now considered an erroneous view. Any antipsychotic can be associated with hyperprolactinaemia, although its frequency and severity differs between the various antipsychotics (Bushe and Shaw, 2007) .
Of course not all hyperprolactinaemia in psychotic patients is caused by antipsychotic drugs. Hyperprolactinaemia has many causes, including pituitary tumours, but also a range of other drugs, stress, and even venesection.
The most obvious clinical consequence of hyperprolactinaemia is hypogonadism, and thus amenorrhoea in young women who are not on the oral contraceptive. A long-term consequence of hypogonadism is osteoporosis -from loss of protective oestrogens or testosterone. Not all have immediate symptoms, such as galactorrhoea. An association between prolactin and osteoporosis was reported by Klibanski et al. (1980) in patients with long-standing pituitary tumours. Holt comprehensively describes the medical causes and complications of hyperprolactinaemia, which is the commonest disorder of the hypothalamic-pituitary axis. The paper by Javaid and Holt gives a timely update on osteoporosis relevant to psychiatrists.
Harvey re-examines the original animal work on hyperprolactinaemia and breast tumours and challenges the widely held view that these animal studies are not relevant to humans. The large Nurses Health study reported by Hankinson and Tworoger (2004 in a healthy population of nonschizophrenic patients, show an increased risk of breast cancer incidence in the upper versus lower quartile of prolactin even at normal levels <500 mIU/L (~23.6 ng/ml). Wang (2002) looked at a large epidemiological study where women were exposed to dopamine agonists (antipsychotic and anti-emetics) and found a 16% increase risk of breast cancer. Further research in schizophrenia patients in the UK finds increased risks of breast cancer around 40% (Disability Rights Commission Report, 2006) . There are potential confounders within these large epidemiological studies, but the case to conduct a specific longitudinal study is strong.
The advent of atypical antipsychotics in the 1990s allowed the treatment of schizophrenia with a relatively lower risk (excluding risperidone) of hyperprolactinaemia compared with treatment with earlier typical antipsychotics. However, as Bushe et al. describe, there are few studies where the primary goal was to report prolactin data -most of the available data come from trials designed to assess the efficacy of drugs. The majority of prolactin data from random-controlled trials does not report categorical rates of hyperprolactinaemia making it difficult for clinicians to evaluate the extent and severity of hyperprolactinaemia associated with different antipsychotics. The data do however show that the highest rates of hyperprolactinaemia are actually associated with some atypical antipsychotics demonstrating this issue is not simply one of typical versus atypical antipsychotic.
Bushe et al. report on data from a naturalistic study in the UK, which gives interesting information on the prevalence and severity of hyperprolactinaemia. These data demonstrate that hyperprolactinaemia is experienced by a significant number of people prescribed antipsychotics in clinical practice. This ranged from almost all patients on some drugs having prolactin levels above the normal range to none on clozapine. This screening was carried out in the absence of clinical symptoms of hyperprolactinaemia. The data also demonstrate that, for some, the level of prolactin elevation was significant with 6.2% of the cohort having a level >2000 mIU/L (~94.3 ng/ml), which exceeds the upper limit of normal 3-4-fold.
With the introduction of antipsychotics with a lower potential for increasing prolactin levels, there has been a renewed research interest in this aspect. Pariante reviews the evidence that psychotic disorder is associated with enlargement of the pituitary and that prolactin raising antipsychotics also seem to increase pituitary volume. This may be due to the proliferation of lactotroph cells that may, in turn, be linked to the increase in pituitary tumours that was reported in Szarfman's retrospective pharmacovigilance study using the FDA database (Szarfman et al., 2006) . This is an important area for further research to clarify the long-term risks.
Twenty years after Klibanski et al. (1980) reported increased rates of osteoporosis in patients with amenorrhoea from long-standing pituitary tumours, several studies confirming this risk in schizophrenia. This topic is comprehensively reviewed by O'keane and discusses how hyperprolactinaemia causes suppression of the reproductive endocrine axis and consequent bone mineral density (BMD) loss. It seems this same process is also occurring in individuals with hypogonadism secondary to antipsychotic-induced hyperprolactinaemia. Howard et al. (2007) showed that prolactin-raising antipsychotics are associated with hip fractures in schizophrenia (OR 2.6), and this has been poorly acknowledged in clinical guidelines or health economic evaluation.
Another consequence of hyperprolactinaemia is sexual dysfunction. Sexual dysfunction is a common feature of many psychiatric diseases, but also a common side effect of many drugs including antipsychotic medication (Kockott and Pfeiffer, 1996; Smith et al., 2002) . It is distressing to some patients (Weiden et al., 2002) and may lead to poor compliance with antipsychotics. The paper by Smith examines drug-induced sexual dysfunction, in particular the effects of hyperprolactinaemia on sexual functioning, and its clinical implications.
Finally, two papers look at some of the clinical and management issues of hyperprolactinaemia. Citrome reviews current guidance issued by both government agencies and medical bodies and organisations. Re-reading a paucity of guidance around diagnosis and monitoring, Walters and Jones discuss how prolactin levels should be monitored, measured and interpreted. Important unanswered questions that need further research are also proposed.
In 2008 we cannot now ignore prolactin elevation. There is good consistent evidence that in any clinically treated population almost half the patients will have hyperprolactinaemia and that persistent hyperprolactinaemia will not be benign.
